Deregulated chromatin remodeling in the pathobiology of brain tumors

NeuroMolecular Medicine

Volumn 15, Issue 1, 2013, Pages 1-24

  Spyropoulou, Anastasia ^a   Piperi, Christina ^a   Adamopoulos, Christos ^a   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Brain tumors; Chromatin remodeling; DNA methylation inhibitors; Gliomas; Histone deacetylation inhibitors; Histone modifications

Indexed keywords

4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; BEVACIZUMAB; BORTEZOMIB; BUTYRIC ACID; CISPLATIN; DNA; DNA METHYLTRANSFERASE INHIBITOR; ENTINOSTAT; ERLOTINIB; ETOPOSIDE; FIRTECAN; GEFITINIB; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE METHYLTRANSFERASE; PACLITAXEL; PANOBINOSTAT; PIVALOYLOXYMETHYL BUTYRATE; RETINOIC ACID; ROMIDEPSIN; SALINOSPORAMIDE A; TEMOZOLOMIDE; TRICHOSTATIN A; UNINDEXED DRUG; VALPROIC ACID; VANDETANIB; VINCRISTINE; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; BRAIN CANCER; CANCER RADIOTHERAPY; CARCINOGENESIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; DEACETYLATION; DNA DAMAGE; DNA METHYLATION; DNA MODIFICATION; DNA REPAIR; DNA REPLICATION; DRUG POTENTIATION; DRUG TARGETING; GENE EXPRESSION; GENE SILENCING; GLIOBLASTOMA; GLIOMA; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; MEDULLOBLASTOMA; NONHUMAN; NUCLEOSOME; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; STEREOTACTIC RADIOSURGERY; TUMOR SUPPRESSOR GENE;

ACETYLATION; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DNA, NEOPLASM; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; MACROMOLECULAR SUBSTANCES; METHYLATION; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NUCLEOSOMES; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84874736040     PISSN: 15351084     EISSN: 15591174     Source Type: Journal    
DOI: 10.1007/s12017-012-8205-y     Document Type: Review

References (173)

1. Aguilera, D. G.; Das, C. M.; Sinnappah-Kang, N. D.; Joyce, C.; Taylor, P. H.; Wen, S.; et al. (2009). Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL. Journal of Neuro-oncology, 93, 303-318.
2. Alaminos, M.; Davalos, V.; Ropero, S.; Setien, F.; Paz, M. F.; Herranz, M.; et al. (2005). EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. Cancer Research, 65, 2565-2571. (Pubitemid 40490052)
3. Alonso, M. E.; Bello, M. J.; Gonzalez-Gomez, P.; Arjona, D.; Lomas, J.; de Campos, J. M.; et al. (2003). Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas. Cancer Genetics and Cytogenetics, 144, 134-142. (Pubitemid 36808960)
4. Alonso, M. E.; Bello, M. J.; Gonzalez-Gomez, P.; Arjona, D.; de Campos, J. M.; Gutierrez, M.; et al. (2004). Aberrant CpG island methylation of multiple genes in ependymal tumors. Journal of Neuro-oncology, 67, 159-165. (Pubitemid 38418264)
5. Alonso, M. M.; Diez-Valle, R.; Manterola, L.; Rubio, A.; Liu, D.; Cortes-Santiago, N.; et al. (2011). Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS ONE, 6, e26740.
6. An, Z.; Gluck, C. B.; Choy, M. L.; & Kaufman, L. J. (2010). Suberoylanilide hydroxamic acid limits migration and invasion of glioma cells in two and three dimensional culture. Cancer Letters, 292, 215-227.
7. Anderton, J. A.; Lindsey, J. C.; Lusher, M. E.; Gilbertson, R. J.; Bailey, S.; Ellison, D. W.; et al. (2008). Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2. Neuro-oncology, 10, 981-994.
8. Arts, J.; Angibaud, P.; Marien, A.; Floren, W.; Janssens, B.; King, P.; et al. (2007). R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. British Journal of Cancer, 97, 1344-1353. (Pubitemid 350114783)
9. Bangert, A.; Hacker, S.; Cristofanon, S.; Debatin, K. M.; & Fulda, S. (2011). Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275. Anti-Cancer Drugs, 22, 494-499.
10. Bao, Y.; & Shen, X. (2007). SnapShot: Chromatin remodeling complexes. Cell, 129, 632.
11. Becker, P. B.; & Horz, W. (2002). ATP-dependent nucleosome remodeling. Annual Review of Biochemistry, 71, 247-273. (Pubitemid 34800221)
12. Berdasco, M.; Ropero, S.; Setien, F.; Fraga, M. F.; Lapunzina, P.; Losson, R.; et al. (2009). Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma. Proceedings of the National Academy of Sciences of the United States of America, 106, 21830-21835.
13. Bhat, K. P.; Pelloski, C. E.; Zhang, Y.; Kim, S. H.; deLaCruz, C.; Rehli, M.; et al. (2008). Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2. FEBS Letters, 582, 3193-3200.
14. Biegel, J. A.; Zhou, J. Y.; Rorke, L. B.; Stenstrom, C.; Wainwright, L. M.; & Fogelgren, B. (1999). Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Research, 59, 74-79. (Pubitemid 29062960)
15. Biegel, J. A.; Tan, L.; Zhang, F.; Wainwright, L.; Russo, P.; & Rorke, L. B. (2002). Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clinical Cancer Research, 8, 3461-3467. (Pubitemid 35340722)
16. Bonisch, C.; Nieratschker, S. M.; Orfanos, N. K.; & Hake, S. B. (2008). Chromatin proteomics and epigenetic regulatory circuits. Expert Review of Proteomics, 5, 105-119. (Pubitemid 351287745)
17. Boulay, J. L.; Ionescu, M. C.; Sivasankaran, B.; Labuhn, M.; Dolder-Schlienger, B.; Taylor, E.; et al. (2009). The 10q25.3-26.1 G protein-coupled receptor gene GPR26 is epigenetically silenced in human gliomas. International Journal of Oncology, 35, 1123-1131.
18. Brodeur, G. M.; Sekhon, G.; & Goldstein, M. N. (1977). Chromosomal aberrations in human neuroblastomas. Cancer, 40, 2256-2263. (Pubitemid 8239715)
19. Brose, K.; Bland, K. S.; Wang, K. H.; Arnott, D.; Henzel, W.; Goodman, C. S.; et al. (1999). Slit proteins bind Robo receptors and have an evolutionarily conserved role in repulsive axon guidance. Cell, 96, 795-806. (Pubitemid 29165083)
20. Bruna, A.; Darken, R. S.; Rojo, F.; Ocana, A.; Penuelas, S.; Arias, A.; et al. (2007). High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell, 11, 147-160. (Pubitemid 46209848)
21. Cadieux, B.; Ching, T. T.; VandenBerg, S. R.; & Costello, J. F. (2006). Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. Cancer Research, 66, 8469-8476. (Pubitemid 44449159)
22. Campos, B.; Bermejo, J. L.; Han, L.; Felsberg, J.; Ahmadi, R.; Grabe, N.; et al. (2011). Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas. Cancer Science, 102, 387-392.
23. Canettieri, G.; Di Marcotullio, L.; Greco, A.; Coni, S.; Antonucci, L.; Infante, P.; et al. (2010). Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. Nature Cell Biology, 12, 132-142.
24. Caren, H.; Djos, A.; Nethander, M.; Sjoberg, R. M.; Kogner, P.; Enstrom, C.; et al. (2011). Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma. BMC Cancer, 11, 66.
25. Cecener, G.; Tunca, B.; Egeli, U.; Bekar, A.; Tezcan, G.; Erturk, E.; et al. (2012). The promoter hypermethylation status of GATA6, MGMT, and FHIT in glioblastoma. Cellular and Molecular Neurobiology, 32, 237-244.
26. Chernov, A. V.; Sounni, N. E.; Remacle, A. G.; & Strongin, A. Y. (2009). Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells. Journal of Biological Chemistry, 284, 12727-12734.
27. Chernov, A. V.; Baranovskaya, S.; Golubkov, V. S.; Wakeman, D. R.; Snyder, E. Y.; Williams, R.; et al. (2010). Microarray-based transcriptional and epigenetic profiling of matrix metalloproteinases, collagens, and related genes in cancer. The Journal of Biological Chemistry, 285, 19647-19659.
28. Cho, K. S.; Elizondo, L. I.; & Boerkoel, C. F. (2004). Advances in chromatin remodeling and human disease. Current Opinion in Genetics & Development, 14, 308-315. (Pubitemid 38686937)
29. Chodavarapu, R. K.; Feng, S.; Bernatavichute, Y. V.; Chen, P. Y.; Stroud, H.; Yu, Y.; et al. (2010). Relationship between nucleosome positioning and DNA methylation. Nature, 466, 388-392.
30. Cogdell, D.; Chung, W.; Liu, Y.; McDonald, J. M.; Aldape, K.; Issa, J. P.; et al. (2011). Tumor-associated methylation of the putative tumor suppressor AJAP1 gene and association between decreased AJAP1 expression and shorter survival in patients with glioma. Chinese Journal of Cancer, 30, 247-253.
31. Costa, F. F. (2008). Non-coding RNAs, epigenetics and complexity. Gene, 410, 9-17.
32. Costa, B. M.; Smith, J. S.; Chen, Y.; Chen, J.; Phillips, H. S.; Aldape, K. D.; et al. (2010). Reversing HOXA9 oncogene activation by PI3 K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Research, 70, 453-462.
33. Dallol, A.; Krex, D.; Hesson, L.; Eng, C.; Maher, E. R.; & Latif, F. (2003). Frequent epigenetic inactivation of the SLIT2 gene in gliomas. Oncogene, 22, 4611-4616. (Pubitemid 36920705)
34. Das, C. M.; Aguilera, D.; Vasquez, H.; Prasad, P.; Zhang, M.; Wolff, J. E.; et al. (2007). Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. Journal of Neuro-oncology, 85, 159-170. (Pubitemid 47629397)
35. Davis, F. G.; McCarthy, B. J.; Freels, S.; Kupelian, V.; & Bondy, M. L. (1999). The conditional probability of survival of patients with primary malignant brain tumors: Surveillance, epidemiology, and end results (SEER) data. Cancer, 85, 485-491. (Pubitemid 29051306)
36. de Bono, J. S.; Kristeleit, R.; Tolcher, A.; Fong, P.; Pacey, S.; Karavasilis, V.; et al. (2008). Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clinical Cancer Research, 14, 6663-6673.
37. DeCristofaro, M. F.; Betz, B. L.; Wang, W.; & Weissman, B. E. (1999). Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors. Oncogene, 18, 7559-7565. (Pubitemid 30035057)
38. Diede, S. J.; Guenthoer, J.; Geng, L. N.; Mahoney, S. E.; Marotta, M.; Olson, J. M.; et al. (2010). DNA methylation of developmental genes in pediatric medulloblastomas identified by denaturation analysis of methylation differences. Proceedings of the National Academy of Sciences of the United States of America, 107, 234-239.
39. Dou, Y.; Milne, T. A.; Tackett, A. J.; Smith, E. R.; Fukuda, A.; Wysocka, J.; et al. (2005). Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell, 121, 873-885. (Pubitemid 40806419)
40. Drappatz, J.; Lee, E. Q.; Hammond, S.; Grimm, S. A.; Norden, A. D.; Beroukhim, R.; et al. (2012). Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. Journal of Neuro-oncology, 107, 133-138.
41. Egler, V.; Korur, S.; Failly, M.; Boulay, J. L.; Imber, R.; Lino, M. M.; et al. (2008). Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death. Clinical Cancer Research, 14, 3132-3140.
42. Ellis, L.; Pan, Y.; Smyth, G. K.; George, D. J.; McCormack, C.; Williams-Truax, R.; et al. (2008). Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clinical Cancer Research, 14, 4500-4510.
43. Elsheikh, S. E.; Green, A. R.; Rakha, E. A.; Powe, D. G.; Ahmed, R. A.; Collins, H. M.; et al. (2009). Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Research, 69, 3802-3809.
44. Entin-Meer, M.; Yang, X.; VandenBerg, S. R.; Lamborn, K. R.; Nudelman, A.; Rephaeli, A.; et al. (2007). In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Neuro-oncology, 9, 82-88. (Pubitemid 46580309)
45. Esteller, M. (2002). CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene, 21, 5427-5440. (Pubitemid 34983479)
46. Esteller, M. (2007). Cancer epigenomics: DNA methylomes and histone-modification maps. Nature Reviews Genetics, 8, 286-298. (Pubitemid 46439286)
47. Farioli-Vecchioli, S.; Tanori, M.; Micheli, L.; Mancuso, M.; Leonardi, L.; Saran, A.; et al. (2007). Inhibition of medulloblastoma tumorigenesis by the antiproliferative and pro-differentiative gene PC3. FASEB Journal, 21, 2215-2225. (Pubitemid 47026456)
48. Felsberg, J.; Yan, P. S.; Huang, T. H.; Milde, U.; Schramm, J.; Wiestler, O. D.; et al. (2006). DNA methylation and allelic losses on chromosome arm 14q in oligodendroglial tumours. Neuropathology and Applied Neurobiology, 32, 517-524. (Pubitemid 44401513)
49. Foltz, G.; Ryu, G. Y.; Yoon, J. G.; Nelson, T.; Fahey, J.; Frakes, A.; et al. (2006). Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma. Cancer Research, 66, 6665-6674. (Pubitemid 44085623)
50. Fotheringham, S.; Epping, M. T.; Stimson, L.; Khan, O.; Wood, V.; Pezzella, F.; et al. (2009). Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell, 15, 57-66.
51. Fouladi, M.; Park, J. R.; Stewart, C. F.; Gilbertson, R. J.; Schaiquevich, P.; Sun, J.; et al. (2010). Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. Journal of Clinical Oncology, 28, 3623-3629.
52. Friday, B. B.; Anderson, S. K.; Buckner, J.; Yu, C.; Giannini, C.; Geoffroy, F.; et al. (2012). Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro-oncology, 14, 215-221.
53. Fujisawa, H.; Takabatake, Y.; Fukusato, T.; Tachibana, O.; Tsuchiya, Y.; & Yamashita, J. (2003). Molecular analysis of the rhabdoid predisposition syndrome in a child: A novel germline hSNF5/INI1 mutation and absence of c-myc amplification. Journal of Neuro-oncology, 63, 257-262. (Pubitemid 36874009)
54. Fujita, T.; Igarashi, J.; Okawa, E. R.; Gotoh, T.; Manne, J.; Kolla, V.; et al. (2008). CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. Journal of the National Cancer Institute, 100, 940-949. (Pubitemid 351957513)
55. Furchert, S. E.; Lanvers-Kaminsky, C.; Juurgens, H.; Jung, M.; Loidl, A.; & Fruhwald, M. C. (2007). Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. International Journal of Cancer, 120, 1787-1794. (Pubitemid 46399367)
56. Galanis, E.; Jaeckle, K. A.; Maurer, M. J.; Reid, J. M.; Ames, M. M.; Hardwick, J. S.; et al. (2009). Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. Journal of Clinical Oncology, 27, 2052-2058.
57. Gao, J.; Chen, T.; Liu, J.; Liu, W.; Hu, G.; Guo, X.; et al. (2009). Loss of NECL1, a novel tumor suppressor, can be restored in glioma by HDAC inhibitor-Trichostatin A through Sp1 binding site. Glia, 57, 989-999.
58. Gartel, A. L.; & Kandel, E. S. (2008). miRNAs: Little known mediators of oncogenesis. Seminars in Cancer Biology, 18, 103-110.
59. George, P.; Bali, P.; Annavarapu, S.; Scuto, A.; Fiskus, W.; Guo, F.; et al. (2005). Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood, 105, 1768-1776. (Pubitemid 40223701)
60. Getun, I. V.; Wu, Z. K.; Khalil, A. M.; & Bois, P. R. (2010). Nucleosome occupancy landscape and dynamics at mouse recombination hotspots. EMBO Reports, 11, 555-560.
61. Gojo, I.; Jiemjit, A.; Trepel, J. B.; Sparreboom, A.; Figg, W. D.; Rollins, S.; et al. (2007). Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood, 109, 2781-2790. (Pubitemid 46482071)
62. Guidi, C. J.; Sands, A. T.; Zambrowicz, B. P.; Turner, T. K.; Demers, D. A.; Webster, W.; et al. (2001). Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice. Molecular and Cellular Biology, 21, 3598-3603. (Pubitemid 32381795)
63. Guidi, C. J.; Mudhasani, R.; Hoover, K.; Koff, A.; Leav, I.; Imbalzano, A. N.; et al. (2006). Functional interaction of the retinoblastoma and Ini1/Snf5 tumor suppressors in cell growth and pituitary tumorigenesis. Cancer Research, 66, 8076-8082. (Pubitemid 44299173)
64. Hamilton, D. W.; Lusher, M. E.; Lindsey, J. C.; Ellison, D. W.; & Clifford, S. C. (2005). Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma. Cancer Letters, 227, 75-81. (Pubitemid 41033094)
65. Hayry, V.; Tanner, M.; Blom, T.; Tynninen, O.; Roselli, A.; Ollikainen, M.; et al. (2008). Copy number alterations of the polycomb gene BMI1 in gliomas. Acta Neuropathologica, 116, 97-102.
66. Hsu, Y. F.; Sheu, J. R.; Hsiao, G.; Lin, C. H.; Chang, T. H.; Chiu, P. T.; et al. (2011). p53 in trichostatin A induced C6 glioma cell death. Biochimica et Biophysica Acta, 1810, 504-513.
67. Huang, J.; Chen, K.; Gong, W.; Dunlop, N. M.; Howard, O. M.; Bian, X.; et al. (2009). Regulation of the leucocyte chemoattractant receptor FPR in glioblastoma cells by cell differentiation. Carcinogenesis, 30, 348-355.
68. Huang, W. J.; Lin, C. W.; Lee, C. Y.; Chi, L. L.; Chao, Y. C.; Wang, H. N.; et al. (2011). NBM-HD-3, a novel histone deacetylase inhibitor with anticancer activity through modulation of PTEN and AKT in brain cancer cells. Journal of Ethnopharmacology, 136, 156-167.
69. Inda, M. M.; Munoz, J.; Coullin, P.; Fauvet, D.; Danglot, G.; Tunon, T.; et al. (2006). High promoter hypermethylation frequency of p14/ARF in supratentorial PNET but not in medulloblastoma. Histopathology, 48, 579-587.
70. Jackson, E. M.; Sievert, A. J.; Gai, X.; Hakonarson, H.; Judkins, A. R.; Tooke, L.; et al. (2009). Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors. Clinical Cancer Research, 15, 1923-1930.
71. Jane, E. P.; Premkumar, D. R.; Addo-Yobo, S. O.; & Pollack, I. F. (2009). Abrogation of mitogen-activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells. The Journal of Pharmacology and Experimental Therapeutics, 331, 327-337.
72. Johnstone, R. W. (2002). Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nature Reviews Drug Discovery, 1, 287-299. (Pubitemid 37361445)
73. Jung, Y.; Park, J.; Bang, Y. J.; & Kim, T. Y. (2008). Gene silencing of TSPYL5 mediated by aberrant promoter methylation in gastric cancers. Laboratory Investigation, 88, 153-160. (Pubitemid 351161273)
74. Khan, O.; & La Thangue, N. B. (2012). HDAC inhibitors in cancer biology: Emerging mechanisms and clinical applications. Immunology and Cell Biology, 90, 85-94.
75. Kim, T. Y.; Zhong, S.; Fields, C. R.; Kim, J. H.; & Robertson, K. D. (2006). Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Research, 66, 7490-7501. (Pubitemid 44289203)
76. Knobbe, C. B.; Reifenberger, J.; Blaschke, B.; & Reifenberger, G. (2004). Hypermethylation and transcriptional downregulation of the carboxyl-terminal modulator protein gene in glioblastomas. Journal of the National Cancer Institute, 96, 483-486. (Pubitemid 38443652)
77. Konduri, S. D.; Srivenugopal, K. S.; Yanamandra, N.; Dinh, D. H.; Olivero, W. C.; Gujrati, M.; et al. (2003). Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells. Oncogene, 22, 4509-4516. (Pubitemid 36920694)
78. Kongkham, P. N.; Northcott, P. A.; Ra, Y. S.; Nakahara, Y.; Mainprize, T. G.; Croul, S. E.; et al. (2008). An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma. Cancer Research, 68, 9945-9953.
79. Kongkham, P. N.; Northcott, P. A.; Croul, S. E.; Smith, C. A.; Taylor, M. D.; & Rutka, J. T. (2010). The SFRP family of WNT inhibitors function as novel tumor suppressor genes epigenetically silenced in medulloblastoma. Oncogene, 29, 3017-3024.
80. Kumar, K. S.; Sonnemann, J.; & Beck, J. F. (2006). Histone deacetylase inhibitors induce cell death in supratentorial primitive neuroectodermal tumor cells. Oncology Reports, 16, 1047-1052.
81. Lehnertz, B.; Ueda, Y.; Derijck, A. A.; Braunschweig, U.; Perez-Burgos, L.; Kubicek, S.; et al. (2003). Suv39 h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin. Current Biology, 13, 1192-1200. (Pubitemid 36872941)
82. Lindsey, J. C.; Anderton, J. A.; Lusher, M. E.; & Clifford, S. C. (2005). Epigenetic events in medulloblastoma development. Neurosurgical Focus, 19, E10.
83. Lindsey, J. C.; Lusher, M. E.; Strathdee, G.; Brown, R.; Gilbertson, R. J.; Bailey, S.; et al. (2006). Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours. International Journal of Cancer, 118, 346-352. (Pubitemid 41779073)
84. Liu, B. L.; Cheng, J. X.; Zhang, X.; Wang, R.; Zhang, W.; Lin, H.; et al. (2010). Global histone modification patterns as prognostic markers to classify glioma patients. Cancer Epidemiology, Biomarkers and Prevention, 19, 2888-2896.
85. Lo, W. S.; Duggan, L.; Emre, N. C.; Belotserkovskya, R.; Lane, W. S.; Shiekhattar, R.; et al. (2001). Snf1-a histone kinase that works in concert with the histone acetyltransferase Gcn5 to regulate transcription. Science, 293, 1142-1146. (Pubitemid 32758096)
86. Loeffler, J. S.; Alexander, E.; 3rd, Shea, W. M.; Wen, P. Y.; Fine, H. A.; Kooy, H. M.; et al. (1992). Radiosurgery as part of the initial management of patients with malignant gliomas. Journal of Clinical Oncology, 10, 1379-1385. (Pubitemid 23059919)
87. Lopez, C. A.; Feng, F. Y.; Herman, J. M.; Nyati, M. K.; Lawrence, T. S.; & Ljungman, M. (2007). Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation. International Journal of Radiation Oncology Biology Physics, 69, 214-220. (Pubitemid 47247526)
88. Lucio-Eterovic, A. K.; Cortez, M. A.; Valera, E. T.; Motta, F. J.; Queiroz, R. G.; Machado, H. R.; et al. (2008). Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer, 8, 243.
89. Maegawa, S.; Yoshioka, H.; Itaba, N.; Kubota, N.; Nishihara, S.; Shirayoshi, Y.; et al. (2001). Epigenetic silencing of PEG3 gene expression in human glioma cell lines. Molecular Carcinogenesis, 31, 1-9. (Pubitemid 32520662)
90. Marino, A. M.; Sofiadis, A.; Baryawno, N.; Johnsen, J. I.; Larsson, C.; Vukojevic, V.; et al. (2011). Enhanced effects by 4-phenylbutyrate in combination with RTK inhibitors on proliferation in brain tumor cell models. Biochemical and Biophysical Research Communications, 411, 208-212.
91. Martinez, R.; & Esteller, M. (2010). The DNA methylome of glioblastoma multiforme. Neurobiology of Disease, 39, 40-46.
92. Masoudi, A.; Elopre, M.; Amini, E.; Nagel, M. E.; Ater, J. L.; Gopalakrishnan, V.; et al. (2008). Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Research, 28, 2437-2442.
93. McDonald, J. M.; Dunlap, S.; Cogdell, D.; Dunmire, V.; Wei, Q.; Starzinski-Powitz, A.; et al. (2006). The SHREW1 gene, frequently deleted in oligodendrogliomas, functions to inhibit cell adhesion and migration. Cancer Biology & Therapy, 5, 300-304.
94. Mehnert, J. M.; & Kelly, W. K. (2007). Histone deacetylase inhibitors: biology and mechanism of action. The Cancer Journal, 13, 23-29.
95. Meissner, A.; Mikkelsen, T. S.; Gu, H.; Wernig, M.; Hanna, J.; Sivachenko, A.; et al. (2008). Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature, 454, 766-770.
96. Michalowski, M. B.; de Fraipont, F.; Michelland, S.; Entz-Werle, N.; Grill, J.; Pasquier, B.; et al. (2006). Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genetics and Cytogenetics, 166, 74-81.
97. Milde, T.; Oehme, I.; Korshunov, A.; Kopp-Schneider, A.; Remke, M.; Northcott, P.; et al. (2010). HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. Clinical Cancer Research, 16, 3240-3252.
98. Minucci, S.; & Pelicci, P. G. (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Reviews Cancer, 6, 38-51. (Pubitemid 43054973)
99. Miyanaga, A.; Gemma, A.; Noro, R.; Kataoka, K.; Matsuda, K.; Nara, M.; et al. (2008). Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Molecular Cancer Therapeutics, 7, 1923-1930.
100. Mottet, D.; Pirotte, S.; Lamour, V.; Hagedorn, M.; Javerzat, S.; Bikfalvi, A.; et al. (2009). HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene, 28, 243-256.
101. Muchardt, C.; Sardet, C.; Bourachot, B.; Onufryk, C.; & Yaniv, M. (1995). A human protein with homology to Saccharomyces cerevisiae SNF5 interacts with the potential helicase hbrm. Nucleic Acids Research, 23, 1127-1132.
102. Muhlisch, J.; Schwering, A.; Grotzer, M.; Vince, G. H.; Roggendorf, W.; Hagemann, C.; et al. (2006). Epigenetic repression of RASSF1A but not CASP8 in supratentorial PNET (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of childhood. Oncogene, 25, 1111-1117. (Pubitemid 43277018)
103. Murr, R. (2010). Interplay between different epigenetic modifications and mechanisms. Advances in Genetics, 70, 101-141.
104. Nagarajan, R. P.; & Costello, J. F. (2009). Molecular epigenetics and genetics in neuro-oncology. Neurotherapeutics, 6, 436-446.
105. Nakahara, Y.; Northcott, P. A.; Li, M.; Kongkham, P. N.; Smith, C.; Yan, H.; et al. (2010). Genetic and epigenetic inactivation of Kruppel-like factor 4 in medulloblastoma. Neoplasia, 12, 20-27.
106. Nakayama, J.; Rice, J. C.; Strahl, B. D.; Allis, C. D.; & Grewal, S. I. (2001). Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science, 292, 110-113. (Pubitemid 32289138)
107. Nikaki, A.; Piperi, C.; & Papavassiliou, A. G. (2012). Role of microRNAs in gliomagenesis: targeting miRNAs in glioblastoma multiforme therapy. Expert Opinion on Investigational Drugs, 21, 1475-1488.
108. Northcott, P. A.; Nakahara, Y.; Wu, X.; Feuk, L.; Ellison, D. W.; Croul, S.; et al. (2009). Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nature Genetics, 41, 465-472.
109. Oppel, F.; Muller, N.; Schackert, G.; Hendruschk, S.; Martin, D.; Geiger, K. D.; et al. (2011). SOX2-RNAi attenuates S-phase entry and induces RhoA-dependent switch to protease-independent amoeboid migration in human glioma cells. Molecular Cancer, 10, 137.
110. Palavalli, L. H.; Prickett, T. D.; Wunderlich, J. R.; Wei, X.; Burrell, A. S.; Porter-Gill, P.; et al. (2009). Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nature Genetics, 41, 518-520.
111. Pang, J. C.; Chang, Q.; Chung, Y. F.; Teo, J. G.; Poon, W. S.; Zhou, L. F.; et al. (2005). Epigenetic inactivation of DLC-1 in supratentorial primitive neuroectodermal tumor. Human Pathology, 36, 36-43. (Pubitemid 40215632)
112. Pang, J. C.; Li, K. K.; Lau, K. M.; Ng, Y. L.; Wong, J.; Chung, N. Y.; et al. (2010). KIAA0495/PDAM is frequently downregulated in oligodendroglial tumors and its knockdown by siRNA induces cisplatin resistance in glioma cells. Brain Pathology, 20, 1021-1032.
113. Papi, A.; Ferreri, A. M.; Rocchi, P.; Guerra, F.; & Orlandi, M. (2010). Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells. Anticancer Research, 30, 535-540.
114. Parsons, D. W.; Jones, S.; Zhang, X.; Lin, J. C.; Leary, R. J.; Angenendt, P.; et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science, 321, 1807-1812.
115. Parsons, D. W.; Li, M.; Zhang, X.; Jones, S.; Leary, R. J.; Lin, J. C.; et al. (2011). The genetic landscape of the childhood cancer medulloblastoma. Science, 331, 435-439.
116. Peyre, M.; Commo, F.; Dantas-Barbosa, C.; Andreiuolo, F.; Puget, S.; Lacroix, L.; et al. (2010). Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis. PLoS ONE, 5, e12932.
117. Pfister, S.; Schlaeger, C.; Mendrzyk, F.; Wittmann, A.; Benner, A.; Kulozik, A.; et al. (2007). Array-based profiling of reference-independent methylation status (aPRIMES) identifies frequent promoter methylation and consecutive downregulation of ZIC2 in pediatric medulloblastoma. Nucleic Acids Research, 35, e51.
118. Pfister, S. M.; Korshunov, A.; Kool, M.; Hasselblatt, M.; Eberhart, C.; & Taylor, M. D. (2010). Molecular diagnostics of CNS embryonal tumors. Acta Neuropathologica, 120, 553-566.
119. Piperi, C.; Themistocleous, M. S.; Papavassiliou, G. A.; Farmaki, E.; Levidou, G.; Korkolopoulou, P.; et al. (2010). High incidence of MGMT and RARbeta promoter methylation in primary glioblastomas: association with histopathological characteristics, inflammatory mediators and clinical outcome. Molecular Medicine, 16, 1-9.
120. Portela, A.; & Esteller, M. (2010). Epigenetic modifications and human disease. Nature Biotechnology, 28, 1057-1068.
121. Potts, C. B.; Albitar, X. M.; Anderson, C. K.; Baritaki, S.; Berkers, C.; Bonavida, B.; et al. (2011a). Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Current Cancer Drug Targets, 11, 254-284.
122. Potts, R. C.; Zhang, P.; Wurster, A. L.; Precht, P.; Mughal, M. R.; Wood, W. H.; 3rd, et al. (2011b). CHD5, a brain-specific paralog of Mi2 chromatin remodeling enzymes, regulates expression of neuronal genes. PLoS ONE, 6, e24515.
123. Premkumar, D. R.; Jane, E. P.; Agostino, N. R.; Didomenico, J. D.; & Pollack, I. F. (2011). Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage. Molecular Carcinogenesis,. doi: 10.1002/mc.21835.
124. Ramalingam, S. S.; Kummar, S.; Sarantopoulos, J.; Shibata, S.; LoRusso, P.; Yerk, M.; et al. (2010). Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Journal of Clinical Oncology, 28, 4507-4512.
125. Rea, S.; Eisenhaber, F.; O'Carroll, D.; Strahl, B. D.; Sun, Z. W.; Schmid, M.; et al. (2000). Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature, 406, 593-599. (Pubitemid 30641039)
126. Restrepo, A.; Smith, C. A.; Agnihotri, S.; Shekarforoush, M.; Kongkham, P. N.; Seol, H. J.; et al. (2011). Epigenetic regulation of glial fibrillary acidic protein by DNA methylation in human malignant gliomas. Neuro-oncology, 13, 42-50.
127. Roberts, C. W.; Galusha, S. A.; McMenamin, M. E.; Fletcher, C. D.; & Orkin, S. H. (2000). Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proceedings of the National Academy of Sciences of the United States of America, 97, 13796-13800.
128. Rottach, A.; Frauer, C.; Pichler, G.; Bonapace, I. M.; Spada, F.; & Leonhardt, H. (2010). The multi-domain protein Np95 connects DNA methylation and histone modification. Nucleic Acids Research, 38, 1796-1804.
129. Rousseau, E.; Ruchoux, M. M.; Scaravilli, F.; Chapon, F.; Vinchon, M.; De Smet, C.; et al. (2003). CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. Neuropathology and Applied Neurobiology, 29, 574-583. (Pubitemid 37548352)
130. Rutka, J. T.; Hubbard, S. L.; Fukuyama, K.; Matsuzawa, K.; Dirks, P. B.; & Becker, L. E. (1994). Effects of antisense glial fibrillary acidic protein complementary DNA on the growth, invasion, and adhesion of human astrocytoma cells. Cancer Research, 54, 3267-3272. (Pubitemid 24208940)
131. Ryan, Q. C.; Headlee, D.; Acharya, M.; Sparreboom, A.; Trepel, J. B.; Ye, J.; et al. (2005). Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. Journal of Clinical Oncology, 23, 3912-3922. (Pubitemid 46218694)
132. Sarcar, B.; Kahali, S.; & Chinnaiyan, P. (2010). Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines. Journal of Neuro-oncology, 99, 201-207.
133. Sawa, H.; Murakami, H.; Kumagai, M.; Nakasato, M.; Yamauchi, S.; Matsuyama, N.; et al. (2004). Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo. Acta Neuropathologica, 107, 523-531. (Pubitemid 38765394)
134. Schmidt, N.; Windmann, S.; Reifenberger, G.; & Riemenschneider, M. J. (2012). DNA hypermethylation and histone modifications downregulate the candidate tumor suppressor gene RRP22 on 22q12 in human gliomas. Brain Pathology, 22, 17-25.
135. Schmitz, M.; Temme, A.; Senner, V.; Ebner, R.; Schwind, S.; Stevanovic, S.; et al. (2007). Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. British Journal of Cancer, 96, 1293-1301. (Pubitemid 46625072)
136. Schneppenheim, R.; Fruhwald, M. C.; Gesk, S.; Hasselblatt, M.; Jeibmann, A.; Kordes, U.; et al. (2010). Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. American Journal of Human Genetics, 86, 279-284.
137. Schuster, J. M.; Longo, M.; & Nelson, P. S. (2003). Differential expression of bikunin (HAI-2/PB), a proposed mediator of glioma invasion, by demethylation treatment. Journal of Neuro-oncology, 64, 219-225. (Pubitemid 37203462)
138. Schwartzentruber, J.; Korshunov, A.; Liu, X. Y.; Jones, D. T.; Pfaff, E.; Jacob, K.; et al. (2012). Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature, 482, 226-231.
139. Seligson, D. B.; Horvath, S.; Shi, T.; Yu, H.; Tze, S.; Grunstein, M.; et al. (2005). Global histone modification patterns predict risk of prostate cancer recurrence. Nature, 435, 1262-1266. (Pubitemid 40943093)
140. Seligson, D. B.; Horvath, S.; McBrian, M. A.; Mah, V.; Yu, H.; Tze, S.; et al. (2009). Global levels of histone modifications predict prognosis in different cancers. The American Journal of Pathology, 174, 1619-1628.
141. Sevenet, N.; Lellouch-Tubiana, A.; Schofield, D.; Hoang-Xuan, K.; Gessler, M.; Birnbaum, D.; et al. (1999a). Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. Human Molecular Genetics, 8, 2359-2368.
142. Sevenet, N.; Sheridan, E.; Amram, D.; Schneider, P.; Handgretinger, R.; & Delattre, O. (1999b). Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. American Journal of Human Genetics, 65, 1342-1348. (Pubitemid 30460384)
143. Simpson, D. J.; Clayton, R. N.; & Farrell, W. E. (2002). Preferential loss of Death Associated Protein kinase expression in invasive pituitary tumours is associated with either CpG island methylation or homozygous deletion. Oncogene, 21, 1217-1224. (Pubitemid 34185238)
144. Singh, M. M.; Manton, C. A.; Bhat, K. P.; Tsai, W. W.; Aldape, K.; Barton, M. C.; et al. (2011). Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors. Neuro-oncology, 13, 894-903.
145. Smits, M.; Nilsson, J.; Mir, S. E.; van der Stoop, P. M.; Hulleman, E.; Niers, J. M.; et al. (2010). miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget, 1, 710-720.
146. Spiller, S. E.; Ditzler, S. H.; Pullar, B. J.; & Olson, J. M. (2008). Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). Journal of Neuro-oncology, 87, 133-141.
147. Steele, N. L.; Plumb, J. A.; Vidal, L.; Tjornelund, J.; Knoblauch, P.; Rasmussen, A.; et al. (2008). A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clinical Cancer Research, 14, 804-810. (Pubitemid 351231163)
148. Tarasenko, N.; Kessler-Icekson, G.; Boer, P.; Inbal, A.; Schlesinger, H.; Phillips, D. R.; et al. (2012). The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity. Investigational New Drugs, 30, 130-143.
149. Teider, N.; Scott, D. K.; Neiss, A.; Weeraratne, S. D.; Amani, V. M.; Wang, Y.; et al. (2010). Neuralized1 causes apoptosis and downregulates Notch target genes in medulloblastoma. Neuro-oncology, 12, 1244-1256.
150. Tepel, M.; Roerig, P.; Wolter, M.; Gutmann, D. H.; Perry, A.; Reifenberger, G.; et al. (2008). Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. International Journal of Cancer, 123, 2080-2086.
151. Tsai, H. C.; Wei, K. C.; Tsai, C. N.; Huang, Y. C.; Chen, P. Y.; Chen, S. M.; et al. (2012). Effect of valproic acid on the outcome of glioblastoma multiforme. British Journal of Neurosurgery, 26, 347-354.
152. Tzao, C.; Tung, H. J.; Jin, J. S.; Sun, G. H.; Hsu, H. S.; Chen, B. H.; et al. (2009). Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus. Modern Pathology, 22, 252-260.
153. Ugur, H. C.; Ramakrishna, N.; Bello, L.; Menon, L. G.; Kim, S. K.; Black, P. M.; et al. (2007). Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model. Journal of Neuro-oncology, 83, 267-275. (Pubitemid 46952237)
154. Uhlmann, K.; Rohde, K.; Zeller, C.; Szymas, J.; Vogel, S.; Marczinek, K.; et al. (2003). Distinct methylation profiles of glioma subtypes. International Journal of Cancer, 106, 52-59. (Pubitemid 36750387)
155. Unoki, M.; Nishidate, T.; & Nakamura, Y. (2004). ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene, 23, 7601-7610. (Pubitemid 39424918)
156. Versteege, I.; Sevenet, N.; Lange, J.; Rousseau-Merck, M. F.; Ambros, P.; Handgretinger, R.; et al. (1998). Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature, 394, 203-206. (Pubitemid 28325977)
157. Vibhakar, R.; Foltz, G.; Yoon, J. G.; Field, L.; Lee, H.; Ryu, G. Y.; et al. (2007). Dickkopf-1 is an epigenetically silenced candidate tumor suppressor gene in medulloblastoma. Neuro-oncology, 9, 135-144. (Pubitemid 46580315)
158. Vladimirova, V.; Mikeska, T.; Waha, A.; Soerensen, N.; Xu, J.; Reynolds, P. C.; et al. (2009). Aberrant methylation and reduced expression of LHX9 in malignant gliomas of childhood. Neoplasia, 11, 700-711.
159. Wagner, J. M.; Hackanson, B.; Lubbert, M.; & Jung, M. (2010). Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clinical Epigenetics, 1, 117-136.
160. Waha, A.; Koch, A.; Hartmann, W.; Mack, H.; Schramm, J.; Sorensen, N.; et al. (2004). Analysis of HIC-1 methylation and transcription in human ependymomas. International Journal of Cancer, 110, 542-549. (Pubitemid 38658019)
161. Waha, A.; Guntner, S.; Huang, T. H.; Yan, P. S.; Arslan, B.; Pietsch, T.; et al. (2005). Epigenetic silencing of the protocadherin family member PCDH-gamma-A11 in astrocytomas. Neoplasia, 7, 193-199. (Pubitemid 40411631)
162. Wang, W.; Xue, Y.; Zhou, S.; Kuo, A.; Cairns, B. R.; & Crabtree, G. R. (1996). Diversity and specialization of mammalian SWI/SNF complexes. Genes & Development, 10, 2117-2130. (Pubitemid 26303868)
163. Wang, G. G.; Allis, C. D.; & Chi, P. (2007). Chromatin remodeling and cancer, part II: ATP-dependent chromatin remodeling. Trends in Molecular Medicine, 13, 373-380. (Pubitemid 47385382)
164. Watanabe, H.; Soejima, K.; Yasuda, H.; Kawada, I.; Nakachi, I.; Yoda, S.; et al. (2008). Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells. Cancer Cell International, 8, 15.
165. Wegener, D.; Deubzer, H. E.; Oehme, I.; Milde, T.; Hildmann, C.; Schwienhorst, A.; et al. (2008). HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells. Anti-Cancer Drugs, 19, 849-857.
166. Wei, L.; Hong, S.; Yoon, Y.; Hwang, S. N.; Park, J. C.; Zhang, Z.; et al. (2012). Early prediction of response to Vorinostat in an orthotopic rat glioma model. NMR in Biomedicine, 25, 1104-1111.
167. Weller, M.; Gorlia, T.; Cairncross, J. G.; van den Bent, M. J.; Mason, W.; Belanger, K.; et al. (2011). Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology, 77, 1156-1164.
168. Wiedemann, S. M.; Mildner, S. N.; Bönisch, C.; Israel, L.; Maiser, A.; Matheisl, S.; et al. (2010). Identification and characterization of two novel primate-specific histone H3 variants, H3.X and H3.Y. The Journal of Cell Biology, 190, 777-791.
169. Wolff, J. E.; Kramm, C.; Kortmann, R. D.; Pietsch, T.; Rutkowski, S.; Jorch, N.; et al. (2008). Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. Journal of Neuro-oncology, 90, 309-314.
170. National Library of Medicine, U.S. National Institutes of Health (NIH), Food and Drug Administration (FDA). (2012). Available at: http://clinicaltrials. gov/.
171. Yi, J. M.; Tsai, H. C.; Glockner, S. C.; Lin, S.; Ohm, J. E.; Easwaran, H.; et al. (2008). Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Research, 68, 8094-8103.
172. Yin, D.; Ong, J. M.; Hu, J.; Desmond, J. C.; Kawamata, N.; Konda, B. M.; et al. (2007). Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clinical Cancer Research, 13, 1045-1052. (Pubitemid 46340384)
173. Yu, C.; Friday, B. B.; Yang, L.; Atadja, P.; Wigle, D.; Sarkaria, J.; et al. (2008). Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells. Neuro-oncology, 10, 309-319.